APAC PRODUCT
Aplagon is developing APACs, biological mimetics of heparin proteoglycan, as potent, first-in-class antithrombotic products. The initial target indications include the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries. APACs also carry a lower bleeding risk than typical systemically acting antithrombotics.
APAC MULTIPLE MECHANISMS OF ACTION
APACs have a number of important and unique properties that include dual antiplatelet (AP) and anticoagulant (AC) modes of action, as well as the ability to target and act locally at the vascular injury site. In addition, they also beneficially influence vascular smooth muscle cells.
OUR COMPANY
Aplagon was established to translate proprietary scientific discoveries on APACs from bed to bedside. The Company is supported by an experienced management team and Board, an excellent scientific network, and backed by a strong syndicate of leading Finnish investors.
